These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22103064)

  • 21. Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.
    Koot D; Cromarty D
    Drug Deliv Transl Res; 2015 Jun; 5(3):257-67. PubMed ID: 25795051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.
    Werner ME; Cummings ND; Sethi M; Wang EC; Sukumar R; Moore DT; Wang AZ
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):463-468. PubMed ID: 23708084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
    Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
    J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin E derivative-based multifunctional nanoemulsions for overcoming multidrug resistance in cancer.
    Zheng N; Gao Y; Ji H; Wu L; Qi X; Liu X; Tang J
    J Drug Target; 2016 Aug; 24(7):663-9. PubMed ID: 26710274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
    Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y
    Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
    Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
    Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation.
    Hong JW; Lee IH; Kwak YH; Park YT; Sung HC; Kwon IC; Chung H
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3239-47. PubMed ID: 18089717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis.
    Nornoo AO; Osborne DW; Chow DS
    Int J Pharm; 2008 Feb; 349(1-2):108-16. PubMed ID: 17869459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
    Pires LA; Hegg R; Valduga CJ; Graziani SR; Rodrigues DG; Maranhão RC
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):281-7. PubMed ID: 18365196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol® and paclitaxel-loaded nanocapsules.
    Boissenot T; Bordat A; Larrat B; Varna M; Chacun H; Paci A; Poinsignon V; Fattal E; Tsapis N
    J Control Release; 2017 Oct; 264():219-227. PubMed ID: 28867377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
    Dias ML; Carvalho JP; Rodrigues DG; Graziani SR; Maranhão RC
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile.
    He L; Wang GL; Zhang Q
    Int J Pharm; 2003 Jan; 250(1):45-50. PubMed ID: 12480272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo pharmacokinetics, biodistribution and antitumor effect of paclitaxel-loaded micelles based on α-tocopherol succinate-modified chitosan.
    Liang N; Sun S; Hong J; Tian J; Fang L; Cui F
    Drug Deliv; 2016 Oct; 23(8):2651-2660. PubMed ID: 26165423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity.
    Liang L; Lin SW; Dai W; Lu JK; Yang TY; Xiang Y; Zhang Y; Li RT; Zhang Q
    J Control Release; 2012 Jun; 160(3):618-29. PubMed ID: 22410114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
    Slingerland M; Guchelaar HJ; Rosing H; Scheulen ME; van Warmerdam LJ; Beijnen JH; Gelderblom H
    Clin Ther; 2013 Dec; 35(12):1946-54. PubMed ID: 24290734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel.
    Yin T; Cai H; Liu J; Cui B; Wang L; Yin L; Zhou J; Huo M
    Eur J Pharm Sci; 2016 Feb; 83():79-87. PubMed ID: 26699227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations.
    Tiwari SB; Amiji MM
    J Nanosci Nanotechnol; 2006; 6(9-10):3215-21. PubMed ID: 17048539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines.
    Gill KK; Kaddoumi A; Nazzal S
    Eur J Pharm Sci; 2012 May; 46(1-2):64-71. PubMed ID: 22369858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.